Immunotherapy of Advanced Bladder Cancer - Daniel Petrylak
September 7, 2017
Daniel Petrylak, MD presents response rates and anti-tumor activity of checkpoint inhibition therapy in patients with advanced urothelial carcinoma and immunotherapy as initial therapy in cisplatin-ineligible patients and in patients with cisplatin pretreated disease. Dr. Petrylak discusses trials that are on-going to explore immunotherapy based combinations and the use of immunotherapy in earlier stages of disease.
Watch: Dr. Petryalk present: What is a checkpoint inhibitors and its mechanisms? What is a checkpoint inhibitors and its mechanisms?
Additional content on Immunotherapy of Advanced Bladder Cancer:
Watch - Immunotherapy in Bladder Cancer - Alan Bryce
Watch- Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell
Immunotherapy of Advanced Bladder Cancer: The Next Frontier
EAU 2016 Immunotherapy for bladder cancer – benefits for all patients? - Session Highlights
Systemic Immunotherapy Bladder Cancer.. Get Ready! EVERYDAY UROLOGY- Full text article
Daniel P Petrylak, MD. Professor of Medicine and Urology - Director, GU Translational Working Group, Co-Director, Signal Transduction Program Smilow Cancer Center, Yale University.